Price (delayed)
$5.95
Market cap
$215.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.15
Enterprise value
$217.05M
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes
There are no recent dividends present for ZVRA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.